Maxim Group reaffirmed their hold rating on shares of MAXIMUS (NYSE:MMS) in a report issued on Thursday, Marketbeat.com reports. The firm currently has a $69.00 price target on the health services provider’s stock, up from their prior price target of $66.00.

Several other equities research analysts have also commented on MMS. Canaccord Genuity dropped their price target on MAXIMUS from $62.00 to $61.00 and set a hold rating for the company in a research note on Friday, November 10th. Zacks Investment Research downgraded MAXIMUS from a hold rating to a sell rating in a research report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $67.00.

Shares of MAXIMUS (NYSE MMS) opened at $63.79 on Thursday. The company has a market capitalization of $4,160.58, a PE ratio of 18.99, a price-to-earnings-growth ratio of 2.39 and a beta of 1.21. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.08 and a current ratio of 2.57. MAXIMUS has a 12 month low of $55.18 and a 12 month high of $72.71.

MAXIMUS (NYSE:MMS) last announced its quarterly earnings results on Thursday, November 9th. The health services provider reported $0.81 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.04. The company had revenue of $620.90 million during the quarter, compared to analyst estimates of $606.86 million. MAXIMUS had a return on equity of 22.93% and a net margin of 8.99%. sell-side analysts anticipate that MAXIMUS will post 3.48 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 28th. Stockholders of record on Thursday, February 15th will be given a $0.045 dividend. This represents a $0.18 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Wednesday, February 14th. MAXIMUS’s payout ratio is 5.36%.

In other news, Director Russell A. Beliveau sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $71.73, for a total value of $71,730.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel David Francis sold 3,900 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $63.97, for a total value of $249,483.00. Following the completion of the sale, the general counsel now directly owns 15,090 shares of the company’s stock, valued at approximately $965,307.30. The disclosure for this sale can be found here. Insiders sold 71,417 shares of company stock valued at $4,902,785 in the last ninety days. Company insiders own 3.10% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of MMS. JPMorgan Chase & Co. boosted its position in shares of MAXIMUS by 459.2% in the second quarter. JPMorgan Chase & Co. now owns 25,842 shares of the health services provider’s stock worth $1,619,000 after buying an additional 21,221 shares during the period. New York State Common Retirement Fund boosted its holdings in MAXIMUS by 10.0% in the second quarter. New York State Common Retirement Fund now owns 86,332 shares of the health services provider’s stock valued at $5,407,000 after purchasing an additional 7,815 shares during the last quarter. UBS Asset Management Americas Inc. boosted its holdings in MAXIMUS by 1.7% in the second quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the health services provider’s stock valued at $2,186,000 after purchasing an additional 592 shares during the last quarter. California Public Employees Retirement System boosted its holdings in MAXIMUS by 2.7% in the second quarter. California Public Employees Retirement System now owns 99,900 shares of the health services provider’s stock valued at $6,257,000 after purchasing an additional 2,600 shares during the last quarter. Finally, Voya Investment Management LLC boosted its holdings in MAXIMUS by 10.9% in the second quarter. Voya Investment Management LLC now owns 29,734 shares of the health services provider’s stock valued at $1,862,000 after purchasing an additional 2,932 shares during the last quarter. 96.44% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “MAXIMUS (MMS) Rating Reiterated by Maxim Group” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/11/maximus-mms-rating-reiterated-by-maxim-group.html.

About MAXIMUS

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.